
Stephen Bradford
Patient advocate for NTRK fusion-positive non-small cell lung cancer; shift coordinator at a steel mill in Mobile, Alabama.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
Jul 27, 2026
Navigating NTRK: the patient perspective | S11E1
4:39
4:51
5:06
5:13
5:30
7:33

Justin GaynorHOST
And you're here today, and you'd shared with me before, but maybe for our audience, what did those biomarker tests come back showing?

Stephen BradfordGUEST
So I had read the report, but I was having a hard time understanding a lot of it, but I did look at some of the present characteristics of my tissue sample.

Stephen BradfordGUEST
So it did mention that I had a NTRK1 fusion, and I didn't know what that was.

Stephen BradfordGUEST
So we started looking into that and wasn't really finding very much information on what that was.

Stephen BradfordGUEST
And both doctors did say it was, I was looking at starting chemo and I actually did have one chemo treatment, not the full treatment, just one session.

Justin GaynorHOST
And when you went into that first visit, you know, where they're relaying the genotyping results, you know, what do they tell you about, you know, NTRK and NTRK inhibitors and what you might experience when you start on these drugs?